TNDM Stock Falls on Q2 Earnings Miss, Revenues Beat, Gross Margin Up
Tandem Diabetes posts record Q2 sales and higher margins, but earnings miss sends shares tumbling 20%.
Tandem Diabetes Care: An Earnings Miss Confirms The Bear Case - Downgrade To Sell
Downgrading Tandem Diabetes Care to sell after Q2 2025 earnings confirms core U.S. business weakness and deteriorating profitability. Intense competition from Insulet and Medtronic is eroding Tandem's market share, with rivals showing stronger growth and profitability. Management's credibility is under pressure, due to material guidance downgrades and reactive strategy, despite upcoming product catalysts.
Tandem Diabetes Care, Inc. (TNDM) Q2 2025 Earnings Call Transcript
Tandem Diabetes Care, Inc. (NASDAQ:TNDM ) Q2 2025 Earnings Conference Call August 6, 2025 4:30 PM ET Company Participants John F. Sheridan - President, CEO & Director Leigh A.
Tandem Diabetes Care (TNDM) Reports Q2 Earnings: What Key Metrics Have to Say
The headline numbers for Tandem Diabetes Care (TNDM) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Tandem Diabetes Care, Inc. (TNDM) Reports Q2 Loss, Beats Revenue Estimates
Tandem Diabetes Care, Inc. (TNDM) came out with a quarterly loss of $0.48 per share versus the Zacks Consensus Estimate of a loss of $0.4. This compares to a loss of $0.47 per share a year ago.
Bears are Losing Control Over Tandem Diabetes Care (TNDM), Here's Why It's a 'Buy' Now
Tandem Diabetes Care (TNDM) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Tandem Diabetes Care, Inc. (TNDM) Expected to Beat Earnings Estimates: Should You Buy?
Tandem Diabetes Care (TNDM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Down 27.0% in 4 Weeks, Here's Why You Should You Buy the Dip in Tandem Diabetes Care (TNDM)
The heavy selling pressure might have exhausted for Tandem Diabetes Care (TNDM) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
TNDM Stock Gains on t:slim X2's Compatibility With FreeStyle Libre 3 +
Tandem Diabetes' t:slim X2 pump with Control-IQ+ tech gains U.S. early access using FreeStyle Libre 3 Plus sensor.
Tandem Diabetes Care (TNDM) Up 6.5% Since Last Earnings Report: Can It Continue?
Tandem Diabetes Care (TNDM) reported earnings 30 days ago. What's next for the stock?
Should Tandem Diabetes Stock Stay in Your Portfolio Now?
Investors remain optimistic about TNDM, courtesy of its strong t:slim X2 performance and breakthrough innovations.
TNDM Stock Rises Despite Q1 Earnings Miss, Gross Margin Up
Tandem Diabetes' Q1 bottom line lags estimate. However, the company experiences strong sales growth both in and outside the United States.
